<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353431</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB13/06</org_study_id>
    <secondary_id>ISRCTN55224894</secondary_id>
    <nct_id>NCT00353431</nct_id>
  </id_info>
  <brief_title>Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia</brief_title>
  <official_title>Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the safety and efficacy of a new algorithm for intensive
      s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose
      concentration ≥ 8 mmol/l)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Prospective randomized trials have shown that near-normoglycemic blood glucose
      control using insulin infusions achieves a significant reduction in mortality of severely ill
      patients in intensive care units, of patients with acute myocardial infarction and with
      stroke. This implies that most severely ill patients with hyperglycemia should be treated
      with insulin to reach near-normoglycemia. However, this is not common practice today in
      emergency room admissions outside the intensive care unit, and strategies to achieve
      near-normoglycemia safely outside the ICU setting with s.c. injections (insulin infusions are
      too risky outside the ICU) have not been established.

      AIM: To evaluate an insulin therapy algorithm using s.c. injections which permits effective
      and safe glycemic management of emergency room patients with hyperglycemia.

      DESIGN: Randomized, controlled trial with an open intervention. Patients presenting with
      hyperglycemia on admission to the emergency room are randomized 1:1 either to conventional
      treatment (conventional insulin group) or to intensive treatment (intensive insulin group).

      METHODS: 140 patients admitted to the medical emergency rooms of the University Hospital
      Basel and the Regional Hospital of Solothurn will be included and randomized as described
      above. All patients with plasma glucose levels exceeding 8.0 mmol/l will be included.

      Exclusion criteria include severely immunocompromised patients, patients in shock, patients
      with terminal illnesses on palliative care, type 1 diabetes with or without ketoacidosis and
      patients which require intensive care unit (ICU) or cardial care unit (CCU) therapy.

      PRIMARY ENDPOINT: Time in the glycaemic target range (5.5-7.0 mmol/l) during the period of
      observation of 48 hours (expected to be longer in the intensive insulin group)

      SECONDARY ENDPOINTS: Time to reach the target range. Frequency of hypoglycaemia (plasma
      glucose &lt; 3.8 mmol/l). Frequency of severe hypoglycaemia (plasma glucose &lt; 2.5 mmol/l.
      Frequency of hypokalaemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours</measure>
    <time_frame>48 h</time_frame>
    <description>Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Target Range</measure>
    <time_frame>24 h</time_frame>
    <description>Hours needed to reach 5.5.-7.0 mmol/l (expected to be shorter in the intensive insulin group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Hypoglycemia</measure>
    <time_frame>during observation of 48 hours</time_frame>
    <description>absolute number of participants with hypoglycemia (plasma glucose &lt; 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Severe Hypoglycaemia</measure>
    <time_frame>during observation of 48 hours</time_frame>
    <description>Number of participants with severe hypoglycaemia (plasma glucose &lt; 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Hypokalaemia</measure>
    <time_frame>during observation of 48 hours</time_frame>
    <description>Number of participants with hypokalaemia (potassium &lt; 3.6 mmol/l, safety endpoint, expected to be similar in the two groups)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Hyperglycemias</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional insulin group:
In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive insulin therapy algorithm:
The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novorapid ®, Novo Nordisk, Denmark</intervention_name>
    <description>Comparison of a sliding scale with an intensive s.c. scale</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>insulin aspart,</other_name>
    <other_name>Novolog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients with hyperglycaemia (≥ 8.0 mmol/l) admitted to the medical emergency
             room.

          -  patients with presumed hospitalisation in ER or medical ward of more than 48 h
             duration.

        Exclusion Criteria:

          -  patients in shock (defined as hypotension or shock index &gt; 1 with oliguria, changed
             mental status and metabolic acidosis)

          -  patients with a terminal illness on palliative care

          -  patients with type 1 diabetes

          -  patients with insulin pump therapy

          -  patients with need for hospitalisation in the intensive or coronary care unit.

          -  patients with presumed hospitalisation shorter than 48 hours

          -  known pregnancy (in women with childbearing potential pregnancy test for exclusion
             mandatory)

          -  no informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Keller, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Endocrinology, Diabetes &amp; Clinical Nutrition, Dept of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Endocrinology, Diabetes &amp; Clinical Nutrition, Dept of Internal Medicine,</name>
      <address>
        <city>Basel</city>
        <state>Baselstadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2006</study_first_submitted>
  <study_first_submitted_qc>July 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2006</study_first_posted>
  <results_first_submitted>October 31, 2011</results_first_submitted>
  <results_first_submitted_qc>May 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2012</results_first_posted>
  <last_update_submitted>May 10, 2012</last_update_submitted>
  <last_update_submitted_qc>May 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperglycaemia</keyword>
  <keyword>algorithm</keyword>
  <keyword>emergency</keyword>
  <keyword>s.c. insulin therapy</keyword>
  <keyword>Emergency patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Basel 22.01.2007 until 31.08.2008 Recruitment Solothurn 30.12.2006-29.04.2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Conventional Insulin Group</title>
          <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
        </group>
        <group group_id="P2">
          <title>Intensive Insulin Therapy Algorithm</title>
          <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional Insulin Group</title>
          <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
        </group>
        <group group_id="B2">
          <title>Intensive Insulin Therapy Algorithm</title>
          <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.22" spread="8.77"/>
                    <measurement group_id="B2" value="72.43" spread="11.67"/>
                    <measurement group_id="B3" value="73.30" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours</title>
        <description>Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)</description>
        <time_frame>48 h</time_frame>
        <population>Intension to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Insulin Group</title>
            <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Insulin Therapy Algorithm</title>
            <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
          </group>
        </group_list>
        <measure>
          <title>Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours</title>
          <description>Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)</description>
          <population>Intension to treat</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="14.7"/>
                    <measurement group_id="O2" value="22.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Target Range</title>
        <description>Hours needed to reach 5.5.-7.0 mmol/l (expected to be shorter in the intensive insulin group).</description>
        <time_frame>24 h</time_frame>
        <population>Intension to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Insulin Group</title>
            <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Insulin Therapy Algorithm</title>
            <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Target Range</title>
          <description>Hours needed to reach 5.5.-7.0 mmol/l (expected to be shorter in the intensive insulin group).</description>
          <population>Intension to treat</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="18.4"/>
                    <measurement group_id="O2" value="11.8" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Hypoglycemia</title>
        <description>absolute number of participants with hypoglycemia (plasma glucose &lt; 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)</description>
        <time_frame>during observation of 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Insulin Group</title>
            <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Insulin Therapy Algorithm</title>
            <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Hypoglycemia</title>
          <description>absolute number of participants with hypoglycemia (plasma glucose &lt; 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Severe Hypoglycaemia</title>
        <description>Number of participants with severe hypoglycaemia (plasma glucose &lt; 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)</description>
        <time_frame>during observation of 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Insulin Group</title>
            <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Insulin Therapy Algorithm</title>
            <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Severe Hypoglycaemia</title>
          <description>Number of participants with severe hypoglycaemia (plasma glucose &lt; 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Hypokalaemia</title>
        <description>Number of participants with hypokalaemia (potassium &lt; 3.6 mmol/l, safety endpoint, expected to be similar in the two groups)</description>
        <time_frame>during observation of 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Insulin Group</title>
            <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Insulin Therapy Algorithm</title>
            <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Hypokalaemia</title>
          <description>Number of participants with hypokalaemia (potassium &lt; 3.6 mmol/l, safety endpoint, expected to be similar in the two groups)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 h</time_frame>
      <desc>Adverse event as Hypoglycaemia and hypokalemia Serious adverse events were death or immediate risk of death</desc>
      <group_list>
        <group group_id="E1">
          <title>Conventional Insulin Group</title>
          <description>In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.</description>
        </group>
        <group group_id="E2">
          <title>Intensive Insulin Therapy Algorithm</title>
          <description>The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Blood samples at admission, day 1 und day 2</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Blood glucose measurements according the protocol</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Thomann, MD</name_or_title>
      <organization>Intern Medicine Solothurn, Switzerland</organization>
      <phone>+41326274501</phone>
      <email>endodiab.bss@bluewin.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

